IL-1 blockade in autoinflammatory syndromes1

Annual Review of Medicine

Volumn 65, Issue , 2014, Pages 223-244

  Jesus, Adriana A ^a   Goldbach Mansky, Raphaela ^a  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

Anakinra; Canakinumab; Hereditary periodic fever syndromes; Interleukin 1; Rilonacept

Indexed keywords

C REACTIVE PROTEIN; CERAMIDE; CHOLESTEROL; CRYOPYRIN; GLUCOSE; HEMOGLOBIN A1C; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; URATE;

ARTICLE; AUTOINFLAMMATORY DISEASE; CINCA SYNDROME; CORONARY ARTERY DISEASE; CYTOKINE PRODUCTION; DEFICIENCY OF INTERLEUKIN 1 RECEPTOR ANTAGONIST; DIABETES MELLITUS; DRUG SAFETY; FAMILIAL MEDITERRANEAN FEVER; GENE MUTATION; GOUT; HEREDITARY PERIODIC FEVER; HUMAN; HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME; INNATE IMMUNITY; LOSS OF FUNCTION MUTATION; MAJEED SYNDROME; MONOGENIC DISORDER; PFAPA SYNDROME; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEFICIENCY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SAPHO SYNDROME; SCHNITZLER SYNDROME; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; CARRIER PROTEINS; HEREDITARY AUTOINFLAMMATORY DISEASES; HUMANS; INFLAMMASOMES; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION;

EID: 84897549425     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-061512-150641     Document Type: Article

References (99)

1. McDermottMF, Aksentijevich I, Galon J, et al. 1999. Germline mutations in the extracellular domains of the 55 kDaTNFreceptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 97:133-44 (Pubitemid 29165896)
2. The International FMF Consortium. 1997. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell 90:797-807
3. The French FMF Consortium. 1997. A candidate gene for familial Mediterranean fever. Nat. Genet. 17:25-31
4. McGonagle D, Aziz A, Dickie LJ, et al. 2009. An integrated classification of pediatric inflammatory diseases, based on the concepts of autoinflammation and the immunological disease continuum. Pediatr. Res. 65:38R-45R
5. Kastner DL, Aksentijevich I, Goldbach-Mansky R. 2010. Autoinflammatory disease reloaded: a clinical perspective. Cell 140:784-90
6. Masters SL, Simon A, Aksentijevich I, et al. 2009. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu. Rev. Immunol. 27:621-68
7. Goldbach-Mansky R. 2012. Immunology in clinic review series; focus on autoinflammatory diseases: update on monogenic autoinflammatory diseases: the role of interleukin (IL)-1 and an emerging role for cytokines beyond IL-1. Clin. Exp. Immunol. 167:391-404
8. Hoffman HM, Wright FA, Broide DH, et al. 2000. Identification of a locus on chromosome 1q44 for familial cold urticaria. Am. J. Hum. Genet. 66:1693-98
9. Cuisset L, Drenth JP, Berthelot JM, et al. 1999. Genetic linkage of the Muckle-Wells syndrome to chromosome 1q44. Am. J. Hum. Genet. 65:1054-59
10. Jung M, Ross B, Wienker TF, et al. 1996. A locus for familial cold urticaria maps to distal chromosome 1q: familial cold urticaria andMuckle-Wells-syndrome are probably allelic. Am. J. Hum. Genet. Suppl. 59 (Abstr.)
11. Hoffman HM, Mueller JL, Broide DH, et al. 2001. Mutation of a new gene encoding a putative pyrinlike protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat. Genet. 29:301-5
12. Aksentijevich I, Nowak M, Mallah M, et al. 2002. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a newmember of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum. 46:3340-48 (Pubitemid 35453546)
13. Feldmann J, Prieur AM, Quartier P, et al. 2002. Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am. J. Hum. Genet. 71:198-203
14. Tanaka N, Izawa K, Saito MK, et al. 2011. High incidence of NLRP3 somatic mosaicism in patients with chronic infantile neurologic, cutaneous, articular syndrome: results of an International Multicenter Collaborative Study. Arthritis Rheum. 63:3625-32
15. Aksentijevich I, Masters SL, Ferguson PJ, et al. 2009. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N. Engl. J. Med. 360:2426-37
16. Reddy S, Jia S, Geoffrey R, et al. 2009. An autoinflammatory disease due to homozygous deletion of the IL1RN locus. N. Engl. J. Med. 360:2438-44
17. Dinarello CA. 2009. Immunological and inflammatory functions of the interleukin-1 family. Annu. Rev. Immunol. 27:519-50
18. Netea MG, Nold-Petry CA, Nold MF, et al. 2009. Differential requirement for the activation of the inflammasome for processing and release of IL-1βin monocytes and macrophages. Blood 113:2324-35
19. Kanneganti TD, Lamkanfi M, Nunez G. 2007. Intracellular NOD-like receptors in host defense and disease. Immunity 27:549-59 (Pubitemid 47615512)
20. Medzhitov R. 2007. Recognition of microorganisms and activation of the immune response. Nature 449:819-26 (Pubitemid 47598622)
21. Mariathasan S, Newton K, Monack DM, et al. 2004. Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature 430:213-18 (Pubitemid 38902430)
22. Martinon F, Burns K, Tschopp J. 2002. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-β. Mol. Cell 10:417-26 (Pubitemid 35007355)
23. Bauernfeind F, Hornung V. 2013. Of inflammasomes and pathogens-sensing of microbes by the inflammasome. EMBO Mol. Med. 5:814-26
24. Ting JP, Duncan JA, Lei Y. 2010. How the noninflammasome NLRs function in the innate immune system. Science 327:286-90
25. Haneklaus M, O'Neill LA, Coll RC. 2013. Modulatory mechanisms controlling the NLRP3 inflammasome in inflammation: recent developments. Curr. Opin. Immunol. 25:40-45
26. Agostini L, Martinon F, Burns K, et al. 2004. NALP3 forms an IL-1β-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 20:319-25 (Pubitemid 38388233)
27. Tschopp J, Martinon F, Burns K. 2003. NALPs: a novel protein family involved in inflammation. Nat. Rev. Mol. Cell Biol. 4:95-104
28. Lachmann HJ, Lowe P, Felix SD, et al. 2009. In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes. J. Exp. Med. 206:1029-36
29. Tassi S, Carta S, Delfino L, et al. 2010. Altered redox state of monocytes from cryopyrin-associated periodic syndromes causes accelerated IL-1βsecretion. Proc. Natl. Acad. Sci. USA 107:9789-94
30. Lee GS, Subramanian N, Kim AI, et al. 2012. The calcium-sensing receptor regulates the NLRP3 inflammasome through Ca2+ and cAMP. Nature 492:123-27
31. Hoffman HM, Rosengren S, Boyle DL, et al. 2004. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 364:1779-85 (Pubitemid 39488063)
32. Jesus AA, Osman M, Silva CA, et al. 2011. A novel mutation of IL1RN in the deficiency of interleukin-1 receptor antagonist syndrome: description of two unrelated cases from Brazil. Arthritis Rheum. 63:4007- 17
33. Dinarello CA, Simon A, van der Meer JW. 2012. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat. Rev. Drug Discov. 11:633-52
34. Hoffman HM, Throne ML, Amar NJ, et al. 2008. Efficacy and safety of rilonacept (interleukin-1 trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum. 58:2443-52
35. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al. 2009. Use of canakinumab in the cryopyrinassociated periodic syndrome. N. Engl. J. Med. 360:2416-25
36. Goldbach-Mansky R, Dailey NJ, Canna SW, et al. 2006. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1βinhibition. N. Engl. J. Med. 355:581-92
37. Neven B, Marvillet I, Terrada C, et al. 2010. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum. 62:258-67
38. Sibley CH, Plass N, Snow J, et al. 2012. Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes. Arthritis Rheum. 64:2375-86
39. Kuemmerle-Deschner JB, Hachulla E, Cartwright R, et al. 2011. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrinassociated periodic syndrome across different severity phenotypes. Ann. Rheum. Dis. 70:2095-102
40. Booth DR, Gillmore JD, Lachmann HJ, et al. 2000. The genetic basis of autosomal dominant familial Mediterranean fever. QJM 93:217-21 (Pubitemid 30198958)
41. Zemer D, Pras M, Sohar E, et al. 1986. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N. Engl. J. Med. 314:1001-5
42. Ozen S, Bilginer Y, Aktay Ayaz N, et al. 2011. Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine. J. Rheumatol. 38:516-18
43. Hashkes PJ, Spalding SJ, Giannini EH, et al. 2012. Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial. Ann. Intern. Med. 157:533-41
44. Martinon F, Mayor A, Tschopp J. 2009. The inflammasomes: guardians of the body. Annu. Rev. Immunol. 27:229-65
45. Savic S, Dickie LJ, Wittmann M, et al. 2012. Autoinflammatory syndromes and cellular responses to stress: pathophysiology, diagnosis and new treatment perspectives. Best Pract. Res. Clin. Rheumatol. 26:505-33
46. Chae JJ, Wood G, Masters SL, et al. 2006. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1βproduction. Proc. Natl. Acad. Sci. USA 103:9982-87
47. Chae JJ, Cho YH, Lee GS, et al. 2011. Gain-of-function pyrin mutations induce NLRP3 proteinindependent interleukin-1βactivation and severe autoinflammation in mice. Immunity 34:755-68
48. McDermott EM, Smillie DM, Powell RJ. 1997. Clinical spectrum of familial Hibernian fever: a 14-year follow-up study of the index case and extended family. Mayo Clin. Proc. 72:806-17
49. Williamson LM, Hull D, Mehta R, et al. 1982. Familial Hibernian fever. Q. J. Med. 51:469-80
50. Bulua AC, Mogul DB, Aksentijevich I, et al. 2012. Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: a prospective, open-label, dose-escalation study. Arthritis Rheum. 64:908-13
51. Ter Haar N, Lachmann H, Ozen S, et al. 2013. Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann. Rheum. Dis. 72:678-85
52. Lobito AA, Kimberley FC, Muppidi JR, et al. 2006. Abnormal disulfide-linked oligomerization results in ER retention and altered signaling by TNFR1 mutants in TNFR1-associated periodic fever syndrome (TRAPS). Blood 108:1320-27 (Pubitemid 44232031)
53. Simon A, Park H, Maddipati R, et al. 2010. Concerted action of wild-type and mutant TNF receptors enhances inflammation in TNF receptor 1-associated periodic fever syndrome. Proc. Natl. Acad. Sci. USA 107:9801-6
54. Bulua AC, Simon A, Maddipati R, et al. 2011. Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS). J. Exp. Med. 208:519-33
55. Drenth JP, Goertz J, Daha MR, et al. 1996. Immunoglobulin D enhances the release of tumor necrosis factor-α, and interleukin-1βas well as interleukin-1 receptor antagonist from human mononuclear cells. Immunology 88:355-62 (Pubitemid 26225157)
56. Ferguson PJ, Chen S, Tayeh MK, et al. 2005. Homozygous mutations in LPIN2 are responsible for the syndrome of chronic recurrent multifocal osteomyelitis and congenital dyserythropoietic anaemia (Majeed syndrome). J. Med. Genet. 42:551-57 (Pubitemid 40993830)
57. Tallon B, Corkill M. 2006. Peculiarities of PAPA syndrome. Rheumatology 45:1140-43 (Pubitemid 44542104)
58. Stichweh DS, Punaro M, Pascual V. 2005. Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with PAPA syndrome. Pediatr. Dermatol. 22:262-65
59. Lee H, Park SH, Kim SK, et al. 2012. Pyogenic arthritis, pyoderma gangrenosum, and acne syndrome (PAPA syndrome) with E250K mutation in CD2BP1 gene treated with the tumor necrosis factor inhibitor adalimumab. Clin. Exp. Rheumatol. 30:452
60. Edrees AF, Kaplan DL, Abdou NI. 2002. Pyogenic arthritis, pyoderma gangrenosum, and acne syndrome (PAPA syndrome) associated with hypogammaglobulinemia and elevated serum tumor necrosis factor-α levels. J. Clin. Rheumatol. 8:273-75
61. Lindor NM, Arsenault TM, Solomon H, et al. 1997. A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum, and acne: PAPA syndrome. Mayo Clin. Proc. 72:611-15
62. Wise CA, Bennett LB, Pascual V, et al. 2000. Localization of a gene for familial recurrent arthritis. Arthritis Rheum. 43:2041-45
63. Geusau A, Mothes-LukschN, Nahavandi H, et al. 2013. Identification of a homozygous PSTPIP1 mutation in a patient with a PAPA-like syndrome responding to canakinumab treatment. JAMA Dermatol. 149:209- 15
64. Demidowich AP, Freeman AF, Kuhns DB, et al. 2012. Brief report: genotype, phenotype, and clinical course in five patients with PAPA syndrome (pyogenic sterile arthritis, pyoderma gangrenosum, and acne). Arthritis Rheum. 64:2022-27
65. Cortis E, De Benedetti F, Insalaco A, et al. 2004. Abnormal production of tumor necrosis factor (TNF)- α and clinical efficacy of the TNF inhibitor etanercept in a patient with PAPA syndrome [corrected]. J. Pediatr. 145:851-55 (Pubitemid 39586631)
66. ToftelandND, Shaver TS. 2010. Clinical efficacy of etanercept for treatment of PAPA syndrome. J. Clin. Rheumatol. 16:244-45
67. Adam Z, Krejci M, Pour L, et al. 2009. [Evaluation of 2-year treatment of Schnitzler syndrome (urticarial exanthema, monoclonal IgM gammopathy and osteolytic-osteosclerotic skeletal changes) using Anakinra (Kineret)]. Vnitr. Lek. 55:1196-97
68. Alonso D, Elgart GW, Schachner LA. 2003. Blau syndrome: a new kindred. J. Am. Acad. Dermatol. 49:299-302
69. Becker ML, Rose CD. 2005. Blau syndrome and related genetic disorders causing childhood arthritis. Curr. Rheumatol. Rep. 7:427-33
70. Rose CD, Martin TM, Wouters CH. 2011. Blau syndrome revisited. Curr. Opin. Rheumatol. 23:411-18
71. Pascual V, Allantaz F, Arce E, et al. 2005. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J. Exp. Med. 201:1479-86
72. Ruperto N, Brunner HI, Quartier P, et al. 2012. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N. Engl. J. Med. 367:2396-406
73. Lovell DJ, Giannini EH, Reiff AO, et al. 2013. Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis (sJIA). Arthritis Rheum. 65:2486-96
74. Quartier P, Allantaz F, Cimaz R, et al. 2011. Amulticentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann. Rheum. Dis. 70:747-54
75. Nordstrom D, Knight A, Luukkainen R, et al. 2012. Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still's disease. An open, randomized, multicenter study. J. Rheumatol. 39:2008-11
76. Kahn MF, Chamot AM. 1992. SAPHO syndrome. Rheum. Dis. Clin. North Am. 18:225-46
77. Nguyen MT, Borchers A, Selmi C, et al. 2012. The SAPHOsyndrome. Semin. Arthritis Rheum. 42:254-65
78. Carneiro S, Sampaio-Barros PD. 2013. SAPHO syndrome. Rheum. Dis. Clin. North Am. 39:401-18
79. Chamot AM, Benhamou CL, Kahn MF, et al. 1987. [Acne-pustulosis- hyperostosis-osteitis syndrome. Results of a national survey. 85 cases]. Rev. Rhum. Mal. Osteoartic. 54:187-96
80. Boutin RD, Resnick D. 1998. The SAPHO syndrome: an evolving concept for unifying several idiopathic disorders of bone and skin. Am. J. Roentgenol. 170:585-91
81. Giedion A, Holthusen W, Masel LF, et al. 1972. Subacute and chronic "symmetrical" osteomyelitis. Ann. Radiol. 15:329-42
82. Morbach H, Hedrich CM, Beer M, et al. 2013. Autoinflammatory bone disorders. Clin. Immunol. 147:185- 96
83. Hayem G, Bouchaud-Chabot A, Benali K, et al. 1999. SAPHO syndrome: a long-term follow-up study of 120 cases. Semin. Arthritis Rheum. 29:159-71
84. Jansson A, Renner ED, Ramser J, et al. 2007. Classification of non-bacterial osteitis: retrospective study of clinical, immunological and genetic aspects in 89 patients. Rheumatology 46:154-60 (Pubitemid 44932805)
85. Girschick HJ, Raab P, Surbaum S, et al. 2005. Chronic non-bacterial osteomyelitis in children. Ann. Rheum. Dis. 64:279-85
86. Shapiro H, Lutaty A, Ariel A. 2011. Macrophages, meta-inflammation, and immuno-metabolism. ScientificWorldJournal 11:2509-29
87. Hotamisligil GS. 2006. Inflammation and metabolic disorders. Nature 444:860-67 (Pubitemid 46024993)
88. Schlesinger N, Alten RE, Bardin T, et al. 2012. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann. Rheum. Dis. 71:1839-48
89. SchlesingerN, Mysler E, Lin HY, et al. 2011. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann. Rheum. Dis. 70:1264-71
90. So A, De Meulemeester M, Pikhlak A, et al. 2010. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study. Arthritis Rheum. 62:3064-76
91. SchumacherHRJr, Evans RR, Saag KG, et al. 2012. Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study. Arthritis Care Res. 64:1462-70
92. Larsen CM, Faulenbach M, Vaag A, et al. 2009. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 32:1663-68
93. Ridker PM, Howard CP, Walter V, et al. 2012. Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation 126:2739-48
94. Moran A, Bundy B, Becker DJ, et al. 2013. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet 381:1905-15
95. van Asseldonk EJ, Stienstra R, Koenen TB, et al. 2011. Treatment with anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study. J. Clin. Endocrinol. Metab. 96:2119-26
96. Emsley HC, Smith CJ, Georgiou RF, et al. 2005. A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. J. Neurol. Neurosurg. Psychiatry 76:1366-72
97. Abbate A, Van Tassell BW, Biondi-Zoccai G, et al. 2013. Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]. Am. J. Cardiol. 111:1394-400
98. Antin JH, Weisdorf D, Neuberg D, et al. 2002. Interleukin-1 blockade does not prevent acute graft-versushost disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. Blood 100:3479-82
99. A Web database archiving genetic variants in the currently recognized monogenic "autoinflammatory diseases" can be used to interrogate disease-related variants (http://fmf.igh.cnrs.fr/ISSAID/infevers/). Diseases